Montes Archimedes Acquisition Corp - Ordinary Shares - Class A

NASDAQ:MAAC   3:59:43 PM EDT
9.87
+0.01 (+0.10%)
Exchange Changes, Mergers / Acquisitions, Equity Financing / Related

Montes Archimedes Acquisition Says Roivant Is Expected To Have An Initial Market Capitalization Of $7.3 Billion

Published: 05/03/2021 12:29 GMT
Montes Archimedes Acquisition Corp - Ordinary Shares - Class A (MAAC) - Roivant Sciences and Montes Archimedes Acquisition Corp.
(maac) to Combine and Create Publicly Traded Leader in Biopharma and Health Technology.
Montes Archimedes Acquisition Corp - Roivant is Expected to Have an Initial Market Capitalization of $7.3 Billion.
Montes Archimedes Acquisition Corp - Pro Forma Net Cash Position of Up to $2.3 Billion Following Transaction.
Montes Archimedes Acquisition Corp - Transaction Includes $411 Million in Trust at Maac and a Concurrent, Fully Committed $200 Million Pipe Financing.
Montes Archimedes Acquisition Corp - Roivant Are Expected to Trade on Nasdaq Under Ticker Symbol "roiv".
Montes Archimedes Acquisition - Pipe Financing From Healthcare Investors Including Fidelity Management & Research Co, Eventide Asset Management.
Montes Archimedes Acquisition Corp - Transaction is Expected to Deliver Up to $611 Million of Gross Proceeds.
Montes Archimedes Acquisition Corp - Patient Square Capital and Key Roivant Equity Holders and Management Have Agreed to Long-term Lockups.
Montes Archimedes Acquisition - Patient Square Capital Agreed to Convert Additional 30% of Shares of Maac to Earn-out Shares Subject to Threshold.
Montes Archimedes Acquisition Corp - Roivant Will Continue to Operate Under Its Current Management Team Led by Chief Executive Officer Matthew Gline.
Montes Archimedes Acquisition Corp - Roivant Founder Vivek Ramaswamy Will Continue to Serve As Executive Chairman.